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The human complement factor H is an important factor in the control of the alterna- 
tive pathway and also induces the stimulation of B cells and macrophages in vitvo. 
Using a human factor H cDNA clone as probe, two factor H-specific transcripts of 
4.4 and 1.8 kb were detected in four human livers. Both mRNAs were found indepen- 
dently of the expression of an acute phase marker SAA, in these livers, indicating that 
their presence is not linked to an acute phase state. The shorter transcript was cloned 
in two cDNA plasmids H-19 and H-20, lacking only seven amino acids of the N- 
terminus of the mature factor H protein. The deduced protein sequence showed that 
this protein is identical to the N-terminal portion of the large classical factor H of 
150 kDa mol. mass. Parallel to the finding that the N-terminal sequence of factor H is 
expressed by two distinct mRNA species, evidence is presented that the C-terminal 
sequence is also contained on two different transcripts, the common 4.4-kb mRNA 
and an additional 1.0-kb mRNA. A novel, short form of human complement factor H 
of 43 kDa was detected in human sera which represents the translation product of the 
1.8-kb factor H-specific mRNA detected in human liver. Five distinct epitopes 
detected with 6 monoclonal antibodies are present on both the 150-kDa factor H 
protein and the truncated 43-kDa molecule. We conclude that additional H-specific 
mRNAs are found in human liver and that at least one of them is translated yielding a 
truncated form of factor H. 
1 Introduction 
The human complement factor H accelerates the decay of the 
alternative pathway convertase C3bBb and serves as a cofactor 
for the conversion of C3b to hemolytically inactive iC3b by 
complement factor I [l-31. H also binds to B cells by means of 
a receptor [4, 51, and induces proliferation of murine B cells 
and the release of factor I from human B cells [6, 71 as well as 
oxygen radicals from human monocytes [8]. The binding site 
for C3b on H and the cofactor activity of H for factor I are 
localized on a N-terminal 38-kDa tryptic fragment of H [9]. 
We have recently isolated cDNA clones for H from a human 
liver cDNA expression library [lo]. One clone, H-19, was 
sequenced and shown to code for most of the 38-kDa N-termi- 
nal fragment of H although the first 34 amino acids were lack- 
ing. The clone also encoded an additional 106 amino acids 
which are derived from the 142 kDa C-terminal tryptic frag- 
ment,but as this clone also contained a 212 bp 3' untranslated 
region with a polyadenylation signal 15 bp upstream of a 
poly(Af) tail we investigated whether alternative splicing of a 
factor H gene transcript might explain this factor H cDNA. 
As two bands of 4.4 and 1.8 kb were consistently observed in 
human liver, we investigated whether the 1.8-kb mRNA is 
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only produced during acute phase conditions and we searched 
for the translation product of the 1.8-kb mRNA in human 
sera. 
2 Materials and methods 
2.1 Northern blot analysis 
RNA from human liver, murine liver and human tonsils were 
prepared by the method of Chirgwin et al. [ll]. Ten pg of total 
RNA was separated on a formaldehyde-containing agarose gel 
and blotted to nylon filters. Agarose gel electrophoresis, RNA 
transfer and hybridization of blots were done by standard tech- 
niques [12]. Due to the limited biopsy material only a small 
amount of RNA was obtained from normal liver. Poly(A+) 
RNA was isolated from total RNA preparations of human 
acute phase liver. No difference in the hybridization pattern 
with the various probes was observed comparing total RNA 
with poly(A+) mRNA samples. The isolated inserts of the 
different plasmids were labeled with 32P using the random 
priming method [13]. The DNA probes utilized in these 
studies are H-19, coding for the N-terminus of factor H,  the 
Tth 111 I fragments of H-19, the cDNA H-46 coding for the 
C-terminus of factor H,  and a probe for human serum amy- 
loid A, pAl  [14]. Hybridization was performed at 65 "C in the 
absence of formamide. The last washing step was done in 
0.1% SSC for 1 h at 65°C. This stringent wash removes any 
cross-hybridization of the human probe with murine liver 
RNA. 
2.2 Antibodies 
Monoclonal antibodies (mAb) to H,  MAH 1-3 [15] and MAH- 
4 were described previously [lo]. OX-23 and OX-24, also 
directed at H,  were a kind gift from Dr. R. Sim, Oxford, GB. 
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All mAb bind to the 38-kDa N-terminal fragment of H and 
MAH-1, MAH-2, MAH-4 inhibit the binding of H to C3b as 
well as the cofactor function of H for I [9, 15, 161. For some 
experiments polyclonal goat anti-H antisera were used. 
2.3 Factor H 
Factor H was purified from fresh human sera by affinity 
chromatography. One ml of normal human serum was diluted 
in phosphate-buffered saline (PBS) and run over a 1-ml MAH- 
4 Sepharose column (2 mg antibodylml of Sepharose). After 
five washes in PBS containing either 0.5 M NaCl or 0.01% 
sodium dodecyl sulfate (SDS), bound proteins were eluted in 
5 ml 0.015 M triethanolamine, pH 11.5. In parallel, factor H 
was also purified by ion-exchange chromatography as 
described previously [17]. The factor H prepared by ion- 
exchange chromatography had been exposed to some pro- 
teolytic cleavage and the major tryptic fragment of 38 kDa is 
therefore present in this preparation. 
2.4 SDS-polyacryiamide gel electrophoresis (PAGE) and 
Western blots 
One to three pl of human serum or 100 1.11 of eluate was elec- 
trophoresed on a 7.5-15% SDS-PAGE and blotted to nitro- 
cellulose according to the method of Towbin et al. [18]. Blots 
or individual lanes were stained with mAb to H (MAH-1 to 
MAH-4, OX-23 and OX-24) and peroxidase-conjugated anti- 
mouse IgG using standard procedures. 
2.5 Construction and screening of a human liver primer 
extension cDNA library 
Recombinant cDNA clones were prepared from 10 pg total 
liver RNA isolated from human liver (see Fig. 2, lane 4). Syn- 
thesis and insertion of double-stranded cDNA by dG:dC 
homopolymer tailing in the Pst I site of pUC9 used for trans- 
formation of E .  coli strain DK1 were essentially according to 
standard protocols [12]. The oligodT primer was replaced by a 
36-bp oligonucleotide I derived from H-19 (see Fig. 6) to initi- 
ate the synthesis of the first strand. One million colonies were 
obtained per pg pUC9 vector; 1 X 10’ were screened with a 
second 25-bp oligonucleotide I1 derived from H-19 5‘ to the 
first oligonucleotide I (see Fig. 6). The oligonucleotides were 
labeled with 32P y-ATP and T4-kinase (121. Thirty cDNA 
clones which hybridized to both oligonucleotide probes and 
contained an internal Bgl I1 restriction site, present in the very 
5‘ sequence of H-19, were analyzed further. Three clones with 
the largest insert of approximately 200 bp were sequenced 
after subcloning in mp 13 vectors by the Sanger dideoxy chain 
termination method [19]. 
2.6 Immunoelectrophoresis 
Immunoelectrophoresis of acute phase and normal human 
sera was performed according to Scheidegger [20] in a 1% 
agarose gel and 0.03 M barbital buffer, pH 8.6. The agarose 
block was washed and stained with amino black. 
3 Results 
3.1 Expression of additional factor H transcripts in normal 
and acute phase human liver 
Using H-19 to probe Northern blots of human liver RNA two 
bands were always detected (Fig. 1A, lane a). The band at 
4.4 kb has the expected length for a mRNA coding for the 150- 
kDa factor H whereas the 1.8-kb band could have given rise to 
cDNA clone H-19 (size: 1.6 kb). To further investigate the 
two factor H mRNA species from human liver restriction sub- 
fragments of H-19 were employed as probes (Fig. 1B). Two 
Tht 111 I fragments, containing either the 5‘ or 3’ end of the 
H-19 cDNA, hybridized to both the 4.4-kb and the 1.8-kb 
message indicating that H-19 is in fact a faithful reverse trans- 
cript of the 1.8-kb mRNA (Fig. 1A, lanes b and c). As the 4.4- 
kb transcript is also detected by both subfragments of H-19, 
the small mRNA could be an alternatively spliced transcript of 
the factor H gene. In order to identify regions of H not con- 
tained in this alternatively spliced mRNA we probed Northern 
blots of human RNA with H-46, a cDNA clone isolated from 
an expression cDNA library by means of a polyclonal antibody 
and which was found to be derived from the 142-kd C-terminal 
region of H [ 101. This clone was found to hybridize only to the 
4.4-kb and not to the 1.8-kb mRNA (Fig. 2). This confirms 
that the 1.8-kb message is derived from the 5’end of the fac- 
tor H gene and lacks the sequence coding for the C-terminus 
of H as does the cDNA clone H-19. Surprisingly, an additional 
mRNA species of approximately 1-kb was detected with H-46 
which does not hybridize to H-19 (Fig. 2). Human liver there- 
fore expresses three distinct factor H derived mRNAs. 
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Figure 1. (A) Northern blots of 
10 hg total RNA from human liver 
(B) 150 kD H-protein (L), murine liver (M) and human 
NHl p / / / / / / / / / / / / / / / / / / / / I I / J  ,!$-COOH tonsils (T) hybridized with H-19 (a), 
the S’Tht 111 I fragment of H-19 (b) 
tryptx 38kD frqmenf (see (B) and the 3’Tthl l l  I frag- 
ment of H-19 (c). (B) Schematic re- NH, -COOH 
truncated 43kO presentation of the relationship be- 
tween the complete 150-kDa fac- 
tor H protein, the 38-kDa tryptic 
H19 TFK end fragment of H carrying the binding 
: IAAA site for C3b and the newly described 
truncated form of H. Also shown are H19 Slprobe - the regions of H coded for by cDNA 
clones H-19 and H-46 [lo] as well as 
the two Tht 111 I restriction frag- 
rnents of the H-19 insert used for hy- 
bridization of Northern blots in (A). 
- - -  T L M  
r H-potm T p y l  
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Eur. J .  Immunol. 1987.17: 1485-1489 Novel truncated complement factor H transcript and protein 1487 
116246.21 
Figure 2. Northern blots of human liver RNA extracted from liver 
biopsies of three individuals with alcoholic liver disease (lanes 1 to 3) 
and of one acute phase liver (lane 4). Ten pg of total RNA each was 
separated on an agarose gel. The central Northern blot was probed 
with H-19, the right blot with H-46 and the one on the left with a probe 
for human serum amyloid A (SAA probe pA1). 
Figure 3. Western blots of normal (lanes 1-3) and acute phase 
(lanes 4-6) human sera probed with MAH-4. One p1 of human serum 
was electrophoresed on a 7.5-15% SDS-polyacryalamide gel. The 43- 
kDa truncated factor H is present in all samples. The molecular mass 
of the bands is given in kDa. 
The first R N A  used in these experiments was isolated from 
acute phase liver. To investigate the possibility that an even- 
tual alternative splicing of factor H mRNA might be linked to 
acute phase state, as has been postulated by others [21], acute 
phase liver R N A  was compared with liver R N A  from biopsies 
of three patients with alcohol-induced liver disease. The blots 
were hybridized with H-19 and H-46. As a control for the 
presence or absence of acute phase reactions in the various 
liver samples, a probe for human serum amyloid A (SAA 
probe pAl) ,  a very sensitive acute phase marker in man [22], 
was included in these experiments. Fig. 2 shows that the level 
of expression of the two factor H mRNA species is roughly the 
same in all livers and does not correlate with the expression of 
the acute phase protein, SAA. This result implies that the 1.8- 
kb factor H m R N A  and the 1.0-kb mRNA are expressed inde- 
pendently of an acute phase reaction and are constitutively 
synthesized in the liver. 
3.2 Identification of the translation product of the 1.8-kb 
factor H mRNA 
As the 1.8-kb message is present at a high level in liver, a small 
protein with factor H reactivity was looked for in human blood 
which could be encoded by a 1.8-kb mRNA. When normal 
and acute phase sera were separated directly by SDS-PAGE 
and analyzed on a Western blot with MAH-4, a mAb to fac- 
tor H, two distinct bands, one of 150-kDa corresponding to  
factor H and another of approximately 43-kDa were always 
detected (Fig. 3). As with the expression of the 1.8-kb mRNA 
this additional 43-kDa band was found in normal human sera 
Figure 4. Reactivity of the 43-kDa H-related protein with six mAb to 
H recognizing five different epitopes. One hundred pl of the affinity- 
purified eluate was electrophoresed under nonreducing conditions on 
six lanes of a 7 5 1 5 %  SDS-polyacrylamide gel. In parallel, 8 pg of 
factor H purified by ion-exchange chromatography was run on the 
same gel under reducing (H red) and nonreducing (H) conditions. 
Individual lanes were stained with different mAb to H (MAH-1 to 
MAH-4, OX-23 and OX-24). Lanes H and H red were stained with 
MAH-4. The factor H prepared by ion-exchange chromatography had 
been exposed to some proteolytic cleavage and therefore the major 
tryptic fragment of 38-kDa is visible on these blots under reducing but 
not under nonreducing conditions. The 43-kDa form of factor H visi- 
ble in the H preparation obtained by affinity chromatography reacts 
with all the mAb to factor H and is clearly different in molecular mass 
from the major tryptic fragment of H at 38-kDa. 
as well as in sera from patients manifesting an acute phase 
reaction. This 43-kDa protein reacted with six mAb detecting 
five distinct epitopes on the 38-kDa N-terminal tryptic frag- 
ment of factor H [9, 161 (Fig. 4). Of these, MAH-4 and OX- 
24 had reacted with the recombinant protein produced by 
clone H-19 [lo]. The truncated 43-kDa factor H product con- 
tains the same epitopes as they are present on the N-terminal 
portion of the large factor H molecule. 
In immunoelectrophoresis of human sera two precipitation 
arcs with p-electrophoretic mobility were found with goat anti- 
H antisera (Fig. 5). The more acidic precipitation line corre- 
sponded to  the 150-kDa factor H molecule on SDS-PAGE 
and Western blot whereas the more basic one represented the 
novel 43-kDa form factor H (not shown). 
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tor H protein [lo] is a faithful transcript of a 1.8-kb mRNA 
constitutively expressed in human liver. A 1-kb cDNA (H-46) 
coding for the C-terminal epitopes of factor H detected a third 
1.0-kb mRNA in addition to the 4.4-kb large factor H trans- 
cript or Northern blots. All three factor H-derived mRNA 
species are expressed in human livers in the absence of any 
sign of acute phase reaction as assessed by a control hybridiza- 
tion with the SAA probe (Fig. 2). Therefore, the expression of 
the short factor H mRNA is not linked to an acute phase state. 
The question arises whether the three distinct factor H- 
specific transcripts are encoded by three separate genes or 
might be explained by an alternative splicing process of one 
factor H transcript. Southern blots of human chromosomal 
DNA hybridized with H-19 and H-46 revealed multiple bands 
pointing to an approximate gene size of more than 50 kb. 
From these data we cannot exclude that the three mRNA 
species are derived from separate genes. In addition the N- 
terminal sequence obtained for the 43-kDa protein through 
the isolation of the primer extension clone H-20 differs from 
the published amino acid sequence of factor H in two positions 
(see Fig. 6). The differences might be explained by protein 
sequencing errors or allelic variation [24], but may also indi- 
cate that the two factor H proteins are encoded by separate 
genes. As DNA sequence data of H-46 are not yet available, 
we concentrated on the expression of the H-19-encoded pro- 
tein product which should share reactivities with the 150-kDa 
factor H. In all sera tested a 43-kDa factor H protein was 
detected. We consider it highly unlikely that this newly 
described 43-kDa form of factor H is a proteolytic cleavage 
product of the 150-kDa factor H for the following reasons: (a) 
the major proteolytic fragment of H sometimes encountered in 
aged sera is only seen on Western blots under reduced condi- 
tions and has a molecular mass of 38-kDa which is clearly 
distinct from the 43-kDa form of H (see Fig. 4). (b) Using 
polyclonal antibodies to factor H we never detected the 142- 
kDa C-terminal tryptic fragment of H (which is complemen- 
tary to the 38-kDa N-terminal fragment) on unreduced West- 
ern blots of human sera (not shown). (c) The 43-kDa band was 
found whether or not protease inhibitors had been added to 
plasma immediately after separation of blood cells and its 
expression did not increase in plasma that had been left at 
room temperature for 48 h (not shown). The size of this new 
form of H (43 kDa) is in good agreement with the 1.8-kb 
mRNA found in human liver. 
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Figure 5. Immunoeiectrophoresis of acute phase (a) and normal (b) 
human serum developed with a polyclonal antibody to whole human 
serum (top through) and a polyclonal antibody to human factor H 
(central through). Conditions: 1% agarose gel in 0.03 M barbital buf- 
fer, pH 8.6, washing and staining with amido black. Anode is on the 
right. 
3.3 Primer extension clones derived from the 1.8-kb mRNA 
In order to have the complete 1.8-kb mRNA isolated in cDNA 
clones a primer extension liver cDNA library was constructed 
using the information provided by H-19. One primer extension 
clone, H-20, was characterized which extends the sequence by 
28 amino acids. H-19 and H-20 differ by 4 nucleotides at the 
very 5' end of H-19. We think that the H-19 sequence is most 
likely incorrect in this position as this is the start of the second 
strand in cDNA synthesis. In our experience we have never 
observed any incorrect nucleotide incorporation in the middle 
of cDNA clones obtained by primer extension. The very 5'end 
of the 1.8-kb mRNA has sequence homology with the 
oligonucleotide I. It was therefore not possible to obtain 
larger inserts, as the same primer used to start the synthesis of 
the reverse transcript also initiated the synthesis of the second 
strand. The additional sequence information encoded by H-20 
overlaps with the published amino acid sequence for human 
factor H [23]. Two amino acid substitutions are observed in 
position 12 and 16. The additional 28 amino acids represent 
roughly one half of one of the familiar 60 amino acid repeats 
found in factor H [lo]. 
4 Discussion 
The cDNA clone H-19 which was previously thought to be 
derived from the 4.4-kb mRNA coding for the 150-kDa fac- 
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39 40 
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... ... ... ... ... ... ... ... 
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Figure 6. Sequence of the primer extension cDNA clone, H-20, compared with H-19 and the 17-amino acids sequence obtained from the N- 
terminus of factor H [23]. Two mismatches with the published amino acid sequence (shown on top) were found in position 11 and 15. The 
sequence of the oligonucleotide I used to construct the primer extension cDNA library is marked with * * * and the oligonucleotide I1 employed 
for screening this library is indicated with . . . beneath the H-19 sequence. Amino acids are shown by the single-letter code and are numbered 
according to the published factor H protein sequence [23]. 
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We therefore conclude that a novel form of human comple- 
ment factor H with a molecular mass of 43-kDa can be found 
in human serum and represents the translation product of an 
additional H-derived mRNA in human liver. This truncated 
form of factor H is synthesized under normal conditions and 
represents that portion of whole factor H which carries the 
cofactor activity for factor I and the binding for C3b. As to the 
physiological function of the truncated 43-kDa H protein we 
speculate that some of the many known functions of whole H 
(binding to C3b, cofactor activity for I, B cell and monocyte 
stimulation) may be more efficiently mediated by the 43-kDa 
molecule. These hypotheses are at present under investiga- 
tion. 
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